• +1-646-491-9876
    • +91-20-67278686

    Search

    Hepatocellular Carcinoma-Pipeline Review H1 2017

    Hepatocellular Carcinoma-Pipeline Review H1 2017

    • Report Code ID: RW0001834398
    • Category Pharmaceuticals
    • No. of Pages 1014
    • Publication Month Jun-17
    • Publisher Name Global Markets Direct
    Hepatocellular Carcinoma - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Hepatocellular Carcinoma - Pipeline Review, H1 2017, provides an overview of the Hepatocellular Carcinoma (Oncology) pipeline landscape.

    Hepatocellular carcinoma (HCC) is a type of cancer originates from a liver cell (hepatocyte) which becomes cancerous. This type of cancer occurs more often in men than women. Symptoms include abdominal pain or tenderness, especially in the upper-right part, easy bruising or bleeding, enlarged abdomen and yellow skin or eyes (jaundice) . The predisposing factors include alcohol abuse, autoimmune diseases of the liver, hepatitis B or C virus infection, inflammation of the liver that is long-term (chronic) and iron overload in the body (hemochromatosis) . Treatment includes surgery, chemotherapy and radiation therapy.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Hepatocellular Carcinoma - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Hepatocellular Carcinoma (Oncology) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Hepatocellular Carcinoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Hepatocellular Carcinoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 15, 78, 46, 3, 70, 14 and 2 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 1, 10, 4, 1, 28 and 1 molecules, respectively.

    Hepatocellular Carcinoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Hepatocellular Carcinoma (Oncology) .
    - The pipeline guide reviews pipeline therapeutics for Hepatocellular Carcinoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Hepatocellular Carcinoma (Oncology) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Hepatocellular Carcinoma (Oncology) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Hepatocellular Carcinoma (Oncology)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Hepatocellular Carcinoma (Oncology) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Hepatocellular Carcinoma (Oncology) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents 2
    Introduction 8
    Hepatocellular Carcinoma - Overview 9
    Hepatocellular Carcinoma - Therapeutics Development 10
    Hepatocellular Carcinoma - Therapeutics Assessment 41
    Hepatocellular Carcinoma - Companies Involved in Therapeutics Development 61
    Hepatocellular Carcinoma - Drug Profiles 134
    Hepatocellular Carcinoma - Dormant Projects 963
    Hepatocellular Carcinoma - Discontinued Products 970
    Hepatocellular Carcinoma - Product Development Milestones 973
    Appendix 986

    List of Tables

    Number of Products under Development for Hepatocellular Carcinoma, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..3) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..4) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..5) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..6) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..7) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..8) , H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1) , H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..3) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..4) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..5) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..6) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..7) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..8) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..9) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..10) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..11) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..12) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..13) , H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Products under Development by Universities/Institutes, H1 2017 (Contd..1) , H1 2017
    Products under Development by Universities/Institutes, H1 2017 (Contd..2) , H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..1) , H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..2) , H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..3) , H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..4) , H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..5) , H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..6) , H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1) , H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2) , H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3) , H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..4) , H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..5) , H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..6) , H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Hepatocellular Carcinoma - Pipeline by AB Science SA, H1 2017
    Hepatocellular Carcinoma - Pipeline by AbbVie Inc, H1 2017
    Hepatocellular Carcinoma - Pipeline by Abivax SA, H1 2017
    Hepatocellular Carcinoma - Pipeline by Acceleron Pharma Inc, H1 2017
    Hepatocellular Carcinoma - Pipeline by Adaptimmune Therapeutics Plc, H1 2017
    Hepatocellular Carcinoma - Pipeline by Advenchen Laboratories LLC, H1 2017
    Hepatocellular Carcinoma - Pipeline by Alfact Innovation, H1 2017
    Hepatocellular Carcinoma - Pipeline by Amgen Inc, H1 2017
    Hepatocellular Carcinoma - Pipeline by AndroScience Corp, H1 2017
    Hepatocellular Carcinoma - Pipeline by ArQule Inc, H1 2017
    Hepatocellular Carcinoma - Pipeline by Array BioPharma Inc, H1 2017
    Hepatocellular Carcinoma - Pipeline by AstraZeneca Plc, H1 2017
    Hepatocellular Carcinoma - Pipeline by AVEO Pharmaceuticals Inc, H1 2017
    Hepatocellular Carcinoma - Pipeline by Bayer AG, H1 2017
    Hepatocellular Carcinoma - Pipeline by BeiGene Ltd, H1 2017
    Hepatocellular Carcinoma - Pipeline by Bio-Cancer Treatment International Ltd, H1 2017
    Hepatocellular Carcinoma - Pipeline by Biomics Biotechnologies Co Ltd, H1 2017
    Hepatocellular Carcinoma - Pipeline by Bioneer Corp, H1 2017
    Hepatocellular Carcinoma - Pipeline by Blueprint Medicines Corp, H1 2017
    Hepatocellular Carcinoma - Pipeline by Boehringer Ingelheim GmbH, H1 2017
    Hepatocellular Carcinoma - Pipeline by Boston Biomedical Inc, H1 2017
    Hepatocellular Carcinoma - Pipeline by Bristol-Myers Squibb Company, H1 2017
    Hepatocellular Carcinoma - Pipeline by Can-Fite BioPharma Ltd, H1 2017
    Hepatocellular Carcinoma - Pipeline by CASI Pharmaceuticals Inc, H1 2017
    Hepatocellular Carcinoma - Pipeline by CBT Pharmaceuticals Inc, H1 2017
    Hepatocellular Carcinoma - Pipeline by CCRP Therapeutics GmbH, H1 2017
    Hepatocellular Carcinoma - Pipeline by Celgene Corp, H1 2017
    Hepatocellular Carcinoma - Pipeline by Celldex Therapeutics Inc, H1 2017
    Hepatocellular Carcinoma - Pipeline by Celsion Corp, H1 2017
    Hepatocellular Carcinoma - Pipeline by China Medical System Holdings Ltd, H1 2017
    Hepatocellular Carcinoma - Pipeline by Chugai Pharmaceutical Co Ltd, H1 2017
    Hepatocellular Carcinoma - Pipeline by Conatus Pharmaceuticals Inc, H1 2017
    Hepatocellular Carcinoma - Pipeline by Delcath Systems Inc, H1 2017
    Hepatocellular Carcinoma - Pipeline by Dicerna Pharmaceuticals Inc, H1 2017
    Hepatocellular Carcinoma - Pipeline by Double Bond Pharmaceutical International AB, H1 2017
    Hepatocellular Carcinoma - Pipeline by eFFECTOR Therapeutics Inc, H1 2017
    Hepatocellular Carcinoma - Pipeline by Eiger BioPharmaceuticals Inc, H1 2017
    Hepatocellular Carcinoma - Pipeline by Eisai Co Ltd, H1 2017
    Hepatocellular Carcinoma - Pipeline by Eli Lilly and Company, H1 2017
    Hepatocellular Carcinoma - Pipeline by Endocyte Inc, H1 2017
    Hepatocellular Carcinoma - Pipeline by Epeius Biotechnologies Corp, H1 2017
    Hepatocellular Carcinoma - Pipeline by eTheRNA Immunotherapies NV, H1 2017
    Hepatocellular Carcinoma - Pipeline by Exelixis Inc, H1 2017
    Hepatocellular Carcinoma - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
    Hepatocellular Carcinoma - Pipeline by Faron Pharmaceuticals Oy, H1 2017
    Hepatocellular Carcinoma - Pipeline by Galaxy Biotech LLC, H1 2017
    Hepatocellular Carcinoma - Pipeline by Genelux Corp, H1 2017
    Hepatocellular Carcinoma - Pipeline by Genoscience Pharma, H1 2017
    Hepatocellular Carcinoma - Pipeline by Genosco Inc, H1 2017
    Hepatocellular Carcinoma - Pipeline by Gilead Sciences Inc, H1 2017
    Hepatocellular Carcinoma - Pipeline by GlaxoSmithKline Plc, H1 2017
    Hepatocellular Carcinoma - Pipeline by Golden Biotechnology Corp, H1 2017
    Hepatocellular Carcinoma - Pipeline by Green Cross Cell Corp, H1 2017
    Hepatocellular Carcinoma - Pipeline by Green Cross Corp, H1 2017
    Hepatocellular Carcinoma - Pipeline by H3 Biomedicine Inc, H1 2017
    Hepatocellular Carcinoma - Pipeline by HanAll Biopharma Co Ltd, H1 2017
    Hepatocellular Carcinoma - Pipeline by Horizon Pharma Plc, H1 2017
    Hepatocellular Carcinoma - Pipeline by Humorigin Biotechnology Corp, H1 2017
    Hepatocellular Carcinoma - Pipeline by Immatics Biotechnologies GmbH, H1 2017
    Hepatocellular Carcinoma - Pipeline by Immune Therapeutics Inc, H1 2017
    Hepatocellular Carcinoma - Pipeline by Immunicum AB, H1 2017
    Hepatocellular Carcinoma - Pipeline by Immunitor Inc, H1 2017
    Hepatocellular Carcinoma - Pipeline by Immunomedics Inc, H1 2017
    Hepatocellular Carcinoma - Pipeline by Immunovative Therapies Ltd, H1 2017
    Hepatocellular Carcinoma - Pipeline by In-Cell-Art SAS, H1 2017
    Hepatocellular Carcinoma - Pipeline by Incyte Corp, H1 2017
    Hepatocellular Carcinoma - Pipeline by Inovio Pharmaceuticals Inc, H1 2017
    Hepatocellular Carcinoma - Pipeline by Inspyr Therapeutics Inc, H1 2017
    Hepatocellular Carcinoma - Pipeline by InteRNA Technologies BV, H1 2017
    Hepatocellular Carcinoma - Pipeline by Jenrin Discovery Inc, H1 2017
    Hepatocellular Carcinoma - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2017
    Hepatocellular Carcinoma - Pipeline by Johnson & Johnson, H1 2017
    Hepatocellular Carcinoma - Pipeline by KAHR medical Ltd, H1 2017
    Hepatocellular Carcinoma - Pipeline by Karcinolys SAS, H1 2017
    Hepatocellular Carcinoma - Pipeline by Kite Pharma Inc, H1 2017
    Hepatocellular Carcinoma - Pipeline by Komipharm International Co Ltd, H1 2017
    Hepatocellular Carcinoma - Pipeline by Kowa Company Ltd, H1 2017
    Hepatocellular Carcinoma - Pipeline by Les Laboratoires Servier SAS, H1 2017
    Hepatocellular Carcinoma - Pipeline by Ligand Pharmaceuticals Inc, H1 2017
    Hepatocellular Carcinoma - Pipeline by Lixte Biotechnology Holdings Inc, H1 2017
    Hepatocellular Carcinoma - Pipeline by MaxCyte Inc, H1 2017
    Hepatocellular Carcinoma - Pipeline by MedImmune LLC, H1 2017
    Hepatocellular Carcinoma - Pipeline by Medivir AB, H1 2017
    Hepatocellular Carcinoma - Pipeline by Merck & Co Inc, H1 2017
    Hepatocellular Carcinoma - Pipeline by Merck KGaA, H1 2017
    Hepatocellular Carcinoma - Pipeline by Merrimack Pharmaceuticals Inc, H1 2017
    Hepatocellular Carcinoma - Pipeline by Midatech Pharma Plc, H1 2017
    Hepatocellular Carcinoma - Pipeline by Millennium Pharmaceuticals Inc, H1 2017
    Hepatocellular Carcinoma - Pipeline by Mina Therapeutics Ltd, H1 2017
    Hepatocellular Carcinoma - Pipeline by MTG Biotherapeutics Inc, H1 2017
    Hepatocellular Carcinoma - Pipeline by MultiCell Technologies Inc, H1 2017
    Hepatocellular Carcinoma - Pipeline by NeuroVive Pharmaceutical AB, H1 2017
    Hepatocellular Carcinoma - Pipeline by NormOxys Inc, H1 2017
    Hepatocellular Carcinoma - Pipeline by Novartis AG, H1 2017
    Hepatocellular Carcinoma - Pipeline by NovaTarg Therapeutics Inc, H1 2017
    Hepatocellular Carcinoma - Pipeline by Nymox Pharmaceutical Corp, H1 2017
    Hepatocellular Carcinoma - Pipeline by Omeros Corp, H1 2017
    Hepatocellular Carcinoma - Pipeline by Oncolys BioPharma Inc, H1 2017
    Hepatocellular Carcinoma - Pipeline by OncoMed Pharmaceuticals Inc, H1 2017
    Hepatocellular Carcinoma - Pipeline by OncoTherapy Science Inc, H1 2017
    Hepatocellular Carcinoma - Pipeline by Oneness Biotech Co Ltd, H1 2017
    Hepatocellular Carcinoma - Pipeline by Ono Pharmaceutical Co Ltd, H1 2017
    Hepatocellular Carcinoma - Pipeline by Onxeo SA, H1 2017
    Hepatocellular Carcinoma - Pipeline by Otsuka Holdings Co Ltd, H1 2017
    Hepatocellular Carcinoma - Pipeline by Panacea Pharmaceuticals Inc, H1 2017
    Hepatocellular Carcinoma - Pipeline by PepVax Inc, H1 2017
    Hepatocellular Carcinoma - Pipeline by Peregrine Pharmaceuticals Inc, H1 2017
    Hepatocellular Carcinoma - Pipeline by Pfizer Inc, H1 2017
    Hepatocellular Carcinoma - Pipeline by Pharma Mar SA, H1 2017
    Hepatocellular Carcinoma - Pipeline by PharmAbcine Inc, H1 2017
    Hepatocellular Carcinoma - Pipeline by PharmaEssentia Corp, H1 2017
    Hepatocellular Carcinoma - Pipeline by Provecs Medical GmbH, H1 2017
    Hepatocellular Carcinoma - Pipeline by Provectus Biopharmaceuticals Inc, H1 2017
    Hepatocellular Carcinoma - Pipeline by Q BioMed Inc, H1 2017
    Hepatocellular Carcinoma - Pipeline by RedHill Biopharma Ltd, H1 2017
    Hepatocellular Carcinoma - Pipeline by Regulus Therapeutics Inc, H1 2017
    Hepatocellular Carcinoma - Pipeline by Saronic Biotechnology Inc, H1 2017
    Hepatocellular Carcinoma - Pipeline by Shenogen Pharma Group Ltd, H1 2017
    Hepatocellular Carcinoma - Pipeline by Sillajen Biotherapeutics, H1 2017
    Hepatocellular Carcinoma - Pipeline by Simcere Pharmaceutical Group, H1 2017
    Hepatocellular Carcinoma - Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2017
    Hepatocellular Carcinoma - Pipeline by Taiwan Liposome Company Ltd, H1 2017
    Hepatocellular Carcinoma - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017
    Hepatocellular Carcinoma - Pipeline by TC BioPharm Ltd, H1 2017
    Hepatocellular Carcinoma - Pipeline by tella Inc, H1 2017
    Hepatocellular Carcinoma - Pipeline by Tessa Therapeutics Pte Ltd, H1 2017
    Hepatocellular Carcinoma - Pipeline by Therapure Biopharma Inc, H1 2017
    Hepatocellular Carcinoma - Pipeline by Theravectys SA, H1 2017
    Hepatocellular Carcinoma - Pipeline by Threshold Pharmaceuticals Inc, H1 2017
    Hepatocellular Carcinoma - Pipeline by Tiziana Life Sciences Plc, H1 2017
    Hepatocellular Carcinoma - Pipeline by TRACON Pharmaceuticals Inc, H1 2017
    Hepatocellular Carcinoma - Pipeline by Tumorend LLC, H1 2017
    Hepatocellular Carcinoma - Pipeline by UbiVac LLC, H1 2017
    Hepatocellular Carcinoma - Pipeline by VasGene Therapeutics Inc, H1 2017
    Hepatocellular Carcinoma - Pipeline by Vaxon Biotech, H1 2017
    Hepatocellular Carcinoma - Pipeline by Vect-Horus SAS, H1 2017
    Hepatocellular Carcinoma - Pipeline by Verlyx Pharma Inc, H1 2017
    Hepatocellular Carcinoma - Pipeline by VG Life Sciences Inc, H1 2017
    Hepatocellular Carcinoma - Pipeline by Vicus Therapeutics LLC, H1 2017
    Hepatocellular Carcinoma - Pipeline by Yooyoung Pharm Co Ltd, H1 2017
    Hepatocellular Carcinoma - Dormant Projects, H1 2017
    Hepatocellular Carcinoma - Dormant Projects, H1 2017 (Contd..1) , H1 2017
    Hepatocellular Carcinoma - Dormant Projects, H1 2017 (Contd..2) , H1 2017
    Hepatocellular Carcinoma - Dormant Projects, H1 2017 (Contd..3) , H1 2017
    Hepatocellular Carcinoma - Dormant Projects, H1 2017 (Contd..4) , H1 2017
    Hepatocellular Carcinoma - Dormant Projects, H1 2017 (Contd..5) , H1 2017
    Hepatocellular Carcinoma - Dormant Projects, H1 2017 (Contd..6) , H1 2017
    Hepatocellular Carcinoma - Discontinued Products, H1 2017
    Hepatocellular Carcinoma - Discontinued Products, H1 2017 (Contd..1) , H1 2017
    Hepatocellular Carcinoma - Discontinued Products, H1 2017 (Contd..2) , H1 2017

    List of Figures

    Number of Products under Development for Hepatocellular Carcinoma, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Top 10 Routes of Administration, H1 2017
    Number of Products by Stage and Top 10 Routes of Administration, H1 2017
    Number of Products by Top 10 Molecule Types, H1 2017
    Number of Products by Stage and Top 10 Molecule Types, H1 2017
    AB Science SA
    AbbVie Inc
    Abivax SA
    Acceleron Pharma Inc
    Adaptimmune Therapeutics Plc
    Advenchen Laboratories LLC
    Alfact Innovation
    Amgen Inc
    AndroScience Corp
    ArQule Inc
    Array BioPharma Inc
    AstraZeneca Plc
    AVEO Pharmaceuticals Inc
    Bayer AG
    BeiGene Ltd
    Bio-Cancer Treatment International Ltd
    Biomics Biotechnologies Co Ltd
    Bioneer Corp
    Blueprint Medicines Corp
    Boehringer Ingelheim GmbH
    Boston Biomedical Inc
    Bristol-Myers Squibb Company
    Can-Fite BioPharma Ltd
    CASI Pharmaceuticals Inc
    CBT Pharmaceuticals Inc
    CCRP Therapeutics GmbH
    Celgene Corp
    Celldex Therapeutics Inc
    Celsion Corp
    China Medical System Holdings Ltd
    Chugai Pharmaceutical Co Ltd
    Conatus Pharmaceuticals Inc
    Delcath Systems Inc
    Dicerna Pharmaceuticals Inc
    Double Bond Pharmaceutical International AB
    eFFECTOR Therapeutics Inc
    Eiger BioPharmaceuticals Inc
    Eisai Co Ltd
    Eli Lilly and Company
    Endocyte Inc
    Epeius Biotechnologies Corp
    eTheRNA Immunotherapies NV
    Exelixis Inc
    F. Hoffmann-La Roche Ltd
    Faron Pharmaceuticals Oy
    Galaxy Biotech LLC
    Genelux Corp
    Genoscience Pharma
    Genosco Inc
    Gilead Sciences Inc
    GlaxoSmithKline Plc
    Golden Biotechnology Corp
    Green Cross Cell Corp
    Green Cross Corp
    H3 Biomedicine Inc
    HanAll Biopharma Co Ltd
    Horizon Pharma Plc
    Humorigin Biotechnology Corp
    Immatics Biotechnologies GmbH
    Immune Therapeutics Inc
    Immunicum AB
    Immunitor Inc
    Immunomedics Inc
    Immunovative Therapies Ltd
    In-Cell-Art SAS
    Incyte Corp
    Inovio Pharmaceuticals Inc
    Inspyr Therapeutics Inc
    InteRNA Technologies BV
    Jenrin Discovery Inc
    Jiangsu Hengrui Medicine Co Ltd
    Johnson & Johnson
    KAHR medical Ltd
    Karcinolys SAS
    Kite Pharma Inc
    Komipharm International Co Ltd
    Kowa Company Ltd
    Les Laboratoires Servier SAS
    Ligand Pharmaceuticals Inc
    Lixte Biotechnology Holdings Inc
    MaxCyte Inc
    MedImmune LLC
    Medivir AB
    Merck & Co Inc
    Merck KGaA
    Merrimack Pharmaceuticals Inc
    Midatech Pharma Plc
    Millennium Pharmaceuticals Inc
    Mina Therapeutics Ltd
    MTG Biotherapeutics Inc
    MultiCell Technologies Inc
    NeuroVive Pharmaceutical AB
    NormOxys Inc
    Novartis AG
    NovaTarg Therapeutics Inc
    Nymox Pharmaceutical Corp
    Omeros Corp
    Oncolys BioPharma Inc
    OncoMed Pharmaceuticals Inc
    OncoTherapy Science Inc
    Oneness Biotech Co Ltd
    Ono Pharmaceutical Co Ltd
    Onxeo SA
    Otsuka Holdings Co Ltd
    Panacea Pharmaceuticals Inc
    PepVax Inc
    Peregrine Pharmaceuticals Inc
    Pfizer Inc
    Pharma Mar SA
    PharmAbcine Inc
    PharmaEssentia Corp
    Provecs Medical GmbH
    Provectus Biopharmaceuticals Inc
    Q BioMed Inc
    RedHill Biopharma Ltd
    Regulus Therapeutics Inc
    Saronic Biotechnology Inc
    Shenogen Pharma Group Ltd
    Sillajen Biotherapeutics
    Simcere Pharmaceutical Group
    Sun Pharma Advanced Research Company Ltd
    Taiwan Liposome Company Ltd
    Takeda Pharmaceutical Company Ltd
    TC BioPharm Ltd
    tella Inc
    Tessa Therapeutics Pte Ltd
    Therapure Biopharma Inc
    Theravectys SA
    Threshold Pharmaceuticals Inc
    Tiziana Life Sciences Plc
    TRACON Pharmaceuticals Inc
    Tumorend LLC
    UbiVac LLC
    VasGene Therapeutics Inc
    Vaxon Biotech
    Vect-Horus SAS
    Verlyx Pharma Inc
    VG Life Sciences Inc
    Vicus Therapeutics LLC
    Yooyoung Pharm Co Ltd

    Request for Sample

    Report Url http://www.reportsweb.com//hepatocellular-carcinoma-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//hepatocellular-carcinoma-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//hepatocellular-carcinoma-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments